This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Confirming post #30 from a second method, which matters more than confirming it from a second person.
Temperature-controlled material and long-haul travel is a practical problem with practical solutions, none of which are on the packaging.
Quietly grateful for the plain phrasing. Not every thread gets that.
Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials).
Marking that as an opinion rather than a finding.
The arithmetic in post #35 is right; the assumption feeding it is the part to check.
On Personal import allowances, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the range is the interesting bit.
If you can post the two or three numbers you are working from, several people here will check the arithmetic rather than argue about the conclusion.
Answering the question post #36 raises rather than the one it answers.
Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.
I would put the burden of proof on the interesting explanation, not the dull one.
Trying to state the Personal import allowances position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread passes that test.
I had written a reply contradicting post #37 and deleted it. Here is what survived.
Two people in this thread mean different things by Personal import allowances and are disagreeing about the definition while believing they are disagreeing about the facts. Worth pausing to define it.
Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.
One more caveat and then I will stop qualifying: the sample selected itself.
This is the sort of exchange that makes the archive worth searching.
Marking my uncertainty on Personal import allowances explicitly. I am confident about the direction, much less confident about the size, and not confident at all that it generalises past the case in the first post.
Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.
I am reporting what happened, not recommending it.
Agreed on Personal import allowances, with one qualification that I think matters. The reasoning holds for the case as described. Change the starting assumption and it does not, and the starting assumption is the part nobody states.
The arithmetic in post #45 is right; the assumption feeding it is the part to check.
If someone has run Personal import allowances properly I would rather read that than my own reconstruction of it. Posting mine only because the thread has gone quiet.
What I would want before treating Personal import allowances as settled: the method, the sample, and whether anyone tried to find the opposite result. Two of the three are usually missing.
Post #50 put the caveat in the right place and I want to underline it.
Where a compound is approved under a different trade name in another market, searching the local name finds documents the English name does not.
The arithmetic in post #52 is right; the assumption feeding it is the part to check.
The documentation on Personal import allowances is better than this thread and I say that as someone who has posted in the thread.
Personal import allowances has a well-known answer and a correct answer, and the interesting work is establishing that they are the same. Nobody has done that here yet.
Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.
I would rather be precise about what I do not know than vague about what I do.
Offering a way to settle Personal import allowances rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within the noise, the question was not answerable at this precision.
A regional experience posted here should say which year it describes. The archive keeps these permanently and they age faster than anything else on the site.
Genuinely open to being wrong about this one.